Search Results - "Gruosso, T"

Scoring of tumor-infiltrating lymphocytes: From visual estimation to machine learning by Klauschen, F., Müller, K.-R., Binder, A., Bockmayr, M., Hägele, M., Seegerer, P., Wienert, S., Pruneri, G., de Maria, S., Badve, S., Michiels, S., Nielsen, T.O., Adams, S., Savas, P., Symmans, F., Willis, S., Gruosso, T., Park, M., Haibe-Kains, B., Gallas, B., Thompson, A.M., Cree, I., Sotiriou, C., Solinas, C., Preusser, M., Hewitt, S.M., Rimm, D., Viale, G., Loi, S., Loibl, S., Salgado, R., Denkert, C.

“…The extent of tumor-infiltrating lymphocytes (TILs), along with immunomodulatory ligands, tumor-mutational burden and other biomarkers, has been demonstrated…”
Get full text

Ovarian cancer emerging subtypes: Role of oxidative stress and fibrosis in tumour development and response to treatment by Batista, L., Gruosso, T., Mechta-Grigoriou, F.

“…Epithelial ovarian cancer is a silent disease of usually late diagnosis and poor prognosis. Currently treatment options are limited and mainly consist of…”
Get full text

504P - AVID200 neutralizes TGF-beta1 and -beta3, the principal immunosuppressive TGF-beta isoforms overexpressed by tumours, and sensitizes tumours to immune checkpoint inhibitors by Gruosso, T., O’Connor, M., Denis, J.-F., Figueredo, R., Koropatnick, J., Tremblay, G., Tikhomirov, I.A.

“…Resistance to immune checkpoint inhibitors (ICIs) is a major unmet medical need. The TGF-beta pathway is a key immunosuppressive mechanism that correlates with…”
Get full text

AVID200 neutralizes TGF-beta1 and -beta3, the principal immunosuppressive TGF-beta isoforms overexpressed by tumours, and sensitizes tumours to immune checkpoint inhibitors by Gruosso, T., O’Connor, M., Denis, J.-F., Figueredo, R., Koropatnick, J., Tremblay, G., Tikhomirov, I.A.

Get full text

504PAVID200 neutralizes TGF-beta1 and -beta3, the principal immunosuppressive TGF-beta isoforms overexpressed by tumours, and sensitizes tumours to immune checkpoint inhibitors by Gruosso, T, O’Connor, M, Denis, J -F, Figueredo, R, Koropatnick, J, Tremblay, G, Tikhomirov, I A

“…Abstract Background Resistance to immune checkpoint inhibitors (ICIs) is a major unmet medical need. The TGF-beta pathway is a key immunosuppressive mechanism…”
Get full text

Abstract P4-06-03: Unravelling triple-negative breast cancer tumor microenvironment heterogeneity using an integrative multiomic analysis by Bareche, Y, Buisseret, L, Gruosso, T, Girard, E, Venet, D, Dupont, F, Desmedt, C, Park, M, Rothé, F, Stagg, J, Sotiriou, C

“…Abstract Introduction: Triple negative breast cancer (TNBC) constitute 10-20% of all breast cancers and is associated with a worse prognosis and limited…”
Get full text

Abstract P4-03-08: Mechanisms of CD8+ T cell immunosuppression in triple negative breast cancer by Gruosso, T, Gigoux, M, Bertos, N, Zuo, D, Manem, V, Monette, A, Lapointe, R, Haibe-Kains, B, Park, M

“…Abstract Triple negative breast cancer (TNBC), defined as tumors lacking expression of the estrogen receptor (ER), progesterone receptor (PR) and human…”
Get full text

Distinct immune microenvironments stratify triple-negative breast cancer and predict outcome by Gruosso, T., Gigoux, M., Bertos, N., Manem, V.S.K., Guiot, M.-C., Buisseret, L., Salgado, R., Van den Eyden, G., Haibe-Kains, B., Park, M.

Get full text

Abstract PD6-05: Distinct tumor microenvironments stratify triple negative breast cancer into immune subtypes by Gruosso, T, Gigoux, M, Bertos, N, Manem, VS, Zuo, D, Saleg, SM, Souleimanova, M, Zhao, H, Johnson, RM, Monette, A, Muñoz Ramos, V, Hallett, MT, Stagg, J, Lapointe, R, Omeroglu, A, Meterissian, S, Buisseret, L, Van den Eyden, G, Salgado, R, Guiot, M-C, Haibe-Kains, B, Park, M

“…Abstract Background: Triple negative breast cancer (TNBC) are especially difficult to treat effectively. While only 20-30% of TNBC patients respond to…”
Get full text